Thus, folate-liposome-mediated delivery of AS HER-2 ODN has potential as a new means of increasing the responsiveness of head and neck cancer to conventional chemotherapy.
The prognostic significance and clinical implications of HER-2/neu expression and amplification in head and neck cancer will require additional studies.